23andMe Holding Co.

NasdaqCM:ME Stock Report

Market Cap: US$81.1m

23andMe Holding Past Earnings Performance

Past criteria checks 0/6

23andMe Holding's earnings have been declining at an average annual rate of -32.1%, while the Healthcare industry saw earnings growing at 6.3% annually. Revenues have been declining at an average rate of 8.9% per year.

Key information

-32.1%

Earnings growth rate

18.7%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate-8.9%
Return on equity-603.7%
Net Margin-318.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

Apr 16
Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%

Mar 02
Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%

We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate

Jul 13
We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate

23andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected

Jun 15
23andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected

23andMe: Disappointing Results Could Mean Potential Acquisition Target

Sep 27

23andMe: Treacherous Path To Profitability

Aug 26

23andMe drops 8% as CFO resigns

Aug 19

23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target

Aug 11
23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target

23andMe Q1 2023 Earnings Preview

Aug 07

23andMe: Holiday Miracles Not Enough, Growth Path Too Expensive

Jun 15

23andMe: A Genetics Innovator Positioned For Growth

Feb 19

Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues

Feb 18
Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues

23andMe: No Surprises With Recent Earnings, But Long-Term Story Remains Positive

Nov 21

23andMe Stock: Continued Drug-Development Progress Can Deliver Long-Term Gains

Oct 03

Revenue & Expenses Breakdown

How 23andMe Holding makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:ME Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24193-615154174
30 Jun 24199-631157188
31 Mar 24220-667183205
31 Dec 23248-522235219
30 Sep 23270-336226235
30 Jun 23296-327236233
31 Mar 23299-312226223
31 Dec 22308-317233212
30 Sep 22298-315237205
30 Jun 22277-265213197
31 Mar 22272-217188189
31 Dec 21260-215188185
30 Sep 21259-170153176
30 Jun 21255-190146170
31 Mar 21244-184142160
31 Mar 20305-251170181
31 Mar 19441-184241141

Quality Earnings: ME is currently unprofitable.

Growing Profit Margin: ME is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ME is unprofitable, and losses have increased over the past 5 years at a rate of 32.1% per year.

Accelerating Growth: Unable to compare ME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ME is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.4%).

Return on Equity

High ROE: ME has a negative Return on Equity (-603.67%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 17:50
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

23andMe Holding Co. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gaurav GoparajuBerenberg
Daniel GrosslightCitigroup Inc
Poon MahTD Cowen